Cargando…
Molecular Testing Identifies Determinants of Exceptional Response and Guides Precision Therapy in a Patient with Lethal, Treatment-emergent Neuroendocrine Prostate Cancer
Nearly all prostate cancers start out as adenocarcinomas driven by the androgen receptor (AR). Neuroendocrine prostate cancer (NEPC) is a rare, AR-independent subtype with a poor prognosis and limited treatment options. Importantly, because of the widespread use of novel AR-targeting agents, the inc...
Autores principales: | Turina, Claire B, Coleman, Daniel J, Thomas, George V, Fung, Alice W, Alumkal, Joshi J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6758987/ https://www.ncbi.nlm.nih.gov/pubmed/31565603 http://dx.doi.org/10.7759/cureus.5197 |
Ejemplares similares
-
A population-based analysis of clustering identifies a strong genetic contribution to lethal prostate cancer
por: Nelson, Quentin, et al.
Publicado: (2013) -
Integrative molecular network analysis identifies emergent enzalutamide resistance mechanisms in prostate cancer
por: King, Carly J., et al.
Publicado: (2017) -
The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity
por: Storck, William K., et al.
Publicado: (2022) -
Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4
por: Coleman, Daniel J., et al.
Publicado: (2020) -
Multi-Omics Analyses Detail Metabolic Reprogramming in Lipids, Carnitines, and Use of Glycolytic Intermediates between Prostate Small Cell Neuroendocrine Carcinoma and Prostate Adenocarcinoma
por: Gao, Bei, et al.
Publicado: (2019)